Dimiter S Dimitrov

List of Publications by Year
in descending order

89 papers	6,951 citations	66343 42 h-index	62596 80 g-index
101 all docs	101 docs citations	101 times ranked	9275 citing authors

#	Article	IF	Citations
1	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine, 2018, 24, 20-28.	30.7	1,030
2	Anti-CD22â€“chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, 2013, 121, 1165-1174.	1.4	478
3	The SARS-CoV S glycoprotein: expression and functional characterization. Biochemical and Biophysical Research Communications, 2003, 312, 1159-1164.	2.1	329
4	Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12123-12128.	7.1	276
5	A Neutralizing Human Monoclonal Antibody Protects against Lethal Disease in a New Ferret Model of Acute Nipah Virus Infection. PLoS Pathogens, 2009, 5, e1000642.	4.7	251
6	Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochemical and Biophysical Research Communications, 2009, 390, 404-409.	2.1	239
7	Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody*. Journal of Biological Chemistry, 2006, 281, 15829-15836.	3.4	238
8	Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies. Journal of Virology, 2014, 88, 7796-7805.	3.4	212
9	Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. PLoS Biology, 2021, 19, e3001237.	5.6	171
10	Potent Neutralization of Hendra and Nipah Viruses by Human Monoclonal Antibodies. Journal of Virology, 2006, 80, 891-899.	3.4	155
11	Targeting of folate receptor Î² on acute myeloid leukemia blasts with chimeric antigen receptorâ€“expressing T cells. Blood, 2015, 125, 3466-3476.	1.4	148
12	Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell, 2017, 32, 295-309.e12.	16.8	148
13	Exceptionally Potent Cross-Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody. Journal of Infectious Diseases, 2008, 197, 846-853.	4.0	144
14	A Neutralizing Human Monoclonal Antibody Protects African Green Monkeys from Hendra Virus Challenge. Science Translational Medicine, 2011, 3, 105ra103.	12.4	135
15	Therapeutic antibodies, vaccines and antibodyomes. MAbs, 2010, 2, 347-356.	5.2	129
16	Therapeutic Treatment of Nipah Virus Infection in Nonhuman Primates with a Neutralizing Human Monoclonal Antibody. Science Translational Medicine, 2014, 6, 242ra82.	12.4	117
17	Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nature Communications, 2015, 6, 6536.	12.8	115
18	Therapeutic Antibodies: Current State and Future Trends â€“ Is a Paradigm Change Coming Soon?. Methods in Molecular Biology, 2009, 525, 1-27.	0.9	113

#	Article	IF	Citations
19	Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nature Communications, 2015, 6, 8223.	12.8	106
20	Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Science Translational Medicine, 2019, 11, .	12.4	104
21	Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17121-17126.	7.1	100
22	High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. Cell, 2020, 183, 429-441.e16.	28.9	100
23	Engineered Human Antibody Constant Domains with Increased Stability. Journal of Biological Chemistry, 2009, 284, 14203-14210.	3.4	89
24	Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)â€“Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection. Journal of Infectious Diseases, 2016, 213, 1557-1561.	4.0	84
25	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29832-29838.	7.1	81
26	Trispecific CD19-CD20-CD22â€“targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Science Translational Medicine, 2021, 13, .	12.4	77
27	Construction of a Large Phage-Displayed Human Antibody Domain Library with a Scaffold Based On a Newly Identified Highly Soluble, Stable Heavy Chain Variable Domain. Journal of Molecular Biology, 2008, 382, 779-789.	4.2	72
28	Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nature Communications, 2022, 13, 742.	12.8	71
29	Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. Cell Reports, 2021, 37, 110156.	6.4	67
30	A large library based on a novel (CH2) scaffold: Identification of HIV-1 inhibitors. Biochemical and Biophysical Research Communications, 2009, 387, 387-392.	2.1	64
31	Assessment of folate receptor-Î² expression in human neoplastic tissues. Oncotarget, 2015, 6, 14700-14709.	1.8	64
32	Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. Lancet Infectious Diseases, The, 2020, 20, 445-454.	9.1	60
33	Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials, 2015, 41, 141-150.	11.4	58
34	Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antiviral Research, 2017, 143, 30-37.	4.1	56
35	Engineered CH2 domains (nanoantibodies). MAbs, 2009, 1, 26-28.	5.2	55
36	Shortened Engineered Human Antibody CH2 Domains. Journal of Biological Chemistry, 2011, 286, 27288-27293.	3.4	51

#	Article	IF	Citations
37	Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains. Journal of Virology, 2014, 88, 1125-1139.	3.4	51
38	Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma. Cancer Discovery, 2021, 11, 2884-2903.	9.4	51
39	Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. Scientific Reports, 2016, 6, 31629.	3.3	50
40	Construction of a Large NaÃ¯ve Human Phage-Displayed Fab Library Through One-Step Cloning. Methods in Molecular Biology, 2009, 525, 129-142.	0.9	49
41	A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Cell Host and Microbe, 2017, 22, 471-483.e5.	11.0	48
42	Engineered Soluble Monomeric IgG1 CH3 Domain. Journal of Biological Chemistry, 2013, 288, 25154-25164.	3.4	46
43	Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs. Cancer Research, 2021, 81, 671-684.	0.9	39
44	Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Research, 2010, 88, 107-115.	4.1	38
45	Human monoclonal antibodies as candidate therapeutics against emerging viruses. Frontiers of Medicine, 2017, 11, 462-470.	3.4	38
46	A large human domain antibody library combining heavy and light chain CDR3 diversity. Molecular Immunology, 2010, 47, 912-921.	2.2	35
47	Immune Modulating Antibodyâ€“Drug Conjugate (IM-ADC) for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 15716-15726.	6.4	35
48	Identification and characterization of fully human anti-CD22 monoclonal antibodies. MAbs, 2009, 1, 297-303.	5.2	34
49	Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. Science Translational Medicine, 2020, 12, .	12.4	34
50	Engineered Fc based antibody domains and fragments as novel scaffolds. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1977-1982.	2.3	33
51	A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III. PLoS Pathogens, 2019, 15, e1007836.	4.7	32
52	PotentIn VivoNK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein. Journal of Virology, 2017, 91, .	3.4	31
53	Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Vaccine, 2020, 38, 7205-7212.	3.8	31
54	Structure of an isolated unglycosylated antibody C_H2 domain. Acta Crystallographica Section D: Biological Crystallography, 2008, 64, 1062-1067.	2.5	29

#	Article	IF	Citations
55	Construction of a Human Antibody Domain (VH) Library. Methods in Molecular Biology, 2009, 525, 81-99.	0.9	26
56	Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn. MAbs, 2015, 7, 922-930.	5.2	25
57	Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases. MAbs, 2014, 6, 1201-1210.	5.2	24
58	Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. MAbs, 2012, 4, 466-474.	5.2	23
59	HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. Emerging Microbes and Infections, 2017, 6, 1-7.	6.5	21
60	Discovery of Novel Candidate Therapeutics and Diagnostics Based on Engineered Human Antibody Domains. Current Drug Discovery Technologies, 2014, 11, 28-40.	1.2	20
61	A dualâ€specific antiâ€<scp>IGFâ€1/IGFâ€2</scp> human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma. International Journal of Cancer, 2015, 137, 2243-2252.	5.1	19
62	Engineered antibody CH2 domains binding to nucleolin: Isolation, characterization and improvement of aggregation. Biochemical and Biophysical Research Communications, 2017, 485, 446-453.	2.1	19
63	The Antibody Germline/Maturation Hypothesis, Elicitation of Broadly Neutralizing Antibodies Against HIV-1 and Cord Blood IgM Repertoires. Frontiers in Immunology, 2014, 5, 398.	4.8	15
64	A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell Reports Medicine, 2021, 2, 100344.	6.5	14
65	A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo. Cancer Letters, 2022, 525, 97-107.	7.2	12
66	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. Aids, 2018, 32, 1749-1761.	2.2	11
67	Human Domain Antibodies to Conserved Epitopes on HER2 Potently Inhibit Growth of HER2-Overexpressing Human Breast Cancer Cells In Vitro. Antibodies, 2019, 8, 25.	2.5	10
68	Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies. PLoS ONE, 2015, 10, e0126428.	2.5	9
69	Epitope Mapping of M36, a Human Antibody Domain with Potent and Broad HIV-1 Inhibitory Activity. PLoS ONE, 2013, 8, e66638.	2.5	8
70	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. Journal of Virology, 2019, 93, .	3.4	8
71	Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV. Antibodies, 2019, 8, 53.	2.5	8
72	Antibodyâ€"Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. Molecular Cancer Therapeutics, 2021, 20, 2228-2239.	4.1	8

#	Article	IF	Citations
73	Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells. Translational Oncology, 2022, 15, 101265.	3.7	8
74	Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22. Frontiers in Immunology, 2022, 13, 869825.	4.8	8
75	An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding. MAbs, 2020, 12, 1689027.	5.2	7
76	Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22. Journal of Biological Chemistry, 2021, 297, 100966.	3.4	7
77	Human Antibody Domains and Fragments Targeting Neutrophil Elastase as Candidate Therapeutics for Cancer and Inflammation-Related Diseases. International Journal of Molecular Sciences, 2021, 22, 11136.	4.1	7
78	Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies. Biochemical and Biophysical Research Communications, 2012, 425, 931-937.	2.1	6
79	Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody. Translational Oncology, 2021, 14, 101232.	3.7	6
80	Developability Assessment of an Isolated C_H2 Immunoglobulin Domain. Analytical Chemistry, 2021, 93, 1342-1351.	6.5	6
81	Sequential Antigen Panning for Selection of Broadly Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies. Methods in Molecular Biology, 2009, 562, 143-154.	0.9	4
82	An insulin growth factor-I/II-neutralizing monoclonal antibody in combination with epidermal growth factor receptor inhibitors potently inhibits tumor cell growth. Journal of Cancer, 2022, 13, 1830-1836.	2.5	3
83	Germlining of the HIV-1 broadly neutralizing antibody domain m36. Antiviral Research, 2015, 116, 62-66.	4.1	2
84	Functional reconstitution of the MERS CoV receptor binding motif. Molecular Immunology, 2022, 145, 3-16.	2.2	2
85	No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5115-E5115.	7.1	1
86	The reduced form of the antibody CH2 domain. Protein Science, 2021, 30, 1895-1903.	7.6	1
87	Design of a Novel Fabâ€Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use. Small Methods, 2022, 6, 2100966.	8.6	1
88	Abstract 1545: Development of FGFR4-targeted chimeric antigen receptors (CARs) for the treatment of rhabdomyosarcoma. , 2021, , .		0
89	Abstract 1546: Defining the immune microenvironment in Ewing's sarcoma to potentiate IL1RAP-targeted CAR-T immunotherapy. , 2021, , .		0